Horizon Therapeutics Plc - HZNP STOCK NEWS

Horizon Therapeutics plc (NASDAQ: HZNP) announced a donation of $140,000 in scholarships to support economically disadvantaged students at Trinity College Dublin and Waterford Institute of Technology. The funding will assist 12 STEM students at Trinity and 2 students in health sciences and accounting at Waterford, in partnership with The Ireland Funds. Established in 2019, the Horizon Scholars program aims to provide educational opportunities and mentorship to talented students, fostering future leaders in STEM.

Horizon Therapeutics announced positive results from a post hoc analysis of the UPLIZNA N-MOmentum Phase 2/3 trial, revealing that all seven patients who experienced NMOSD attacks while on rituximab had no attacks after switching to UPLIZNA. UPLIZNA, the first FDA-approved B-cell-depleting monoclonal antibody for NMOSD, showed comparable efficacy in patients with and without prior rituximab exposure. Notably, 92% of patients remained attack-free during the randomized-controlled period, with an annualized attack rate dropping to 0.08 attacks per person-year.

Horizon Therapeutics plc (Nasdaq: HZNP) has launched its second annual Thyroid Eye Disease (TED) Awareness Week, running from November 14-20. The initiative includes educational resources through the IdentifEYE TED campaign, aimed at helping individuals recognize symptoms and seek timely care. With nearly 50% of individuals with Graves’ disease potentially developing TED, early diagnosis is crucial to prevent serious vision issues. This year's awareness campaign is supported by proclamations in several U.S. states, reflecting a growing need for public education about TED.

Horizon Therapeutics announced a real-world adherence analysis of TEPEZZA during the AAO 2021 meeting, revealing that over 90% of patients completed the full eight infusions. This high adherence rate highlights strong patient commitment to treatment for Thyroid Eye Disease (TED), with low non-compliance at 1% and only 8% discontinuing due to adverse events. These findings underscore the efficacy of TEPEZZA in providing relief from TED symptoms, offering physicians confidence in its medical management.

Horizon Therapeutics has received a positive recommendation from the CHMP regarding UPLIZNA for treating adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are AQP4-IgG positive. This decision is based on the N-MOmentum trial, which demonstrated a 77% reduction in relapse risk. The treatment is administered via infusion every six months. UPLIZNA is already approved in the U.S. and Japan, with further review pending in the EU, potentially expanding its market availability significantly.

Horizon Therapeutics has initiated a Phase 2b clinical trial for HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist aimed at treating diffuse cutaneous systemic sclerosis, a severe autoimmune disease. This pivotal trial enrolls approximately 300 patients to measure changes in lung capacity after 52 weeks of treatment. Preliminary Phase 2a results indicated a positive trend in skin score improvement and suggested that LPAR1 inhibition may effectively address fibrosis. This milestone represents a crucial step in developing therapies for a condition with high mortality rates.

Horizon Therapeutics plc (Nasdaq: HZNP) has announced its participation in several upcoming virtual conferences. The Guggenheim 3rd Annual Neuro/Immunology Conference will take place on November 15, 2021, at 9 a.m. ET. The Stifel 2021 Health Care Conference is scheduled for November 16, 2021, at 2 p.m. ET. Finally, the Piper Sandler 33rd Annual Health Care Conference is set for November 30, 2021, at 9 a.m. ET. These presentations will be livestreamed and accessible via Horizon's website.